Literature DB >> 20174751

Facts and artefacts of coagulation assays for factor Xa inhibitors.

Sylvia Haas.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20174751     DOI: 10.1160/TH10-01-0080

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  5 in total

1.  The anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban or rivaroxaban.

Authors:  L C Brendel; F Dobler; G Hessling; J Michel; S L Braun; A L Steinsiek; P Groha; R Eckl; I Deisenhofer; A Hyseni; M Roest; I Ott; B Steppich
Journal:  J Interv Card Electrophysiol       Date:  2017-07-22       Impact factor: 1.900

Review 2.  Current and future management of pediatric venous thromboembolism.

Authors:  Bryce A Kerlin
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

3.  Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke.

Authors:  Ritvij Bowry; Stuart Fraser; Joancy M Archeval-Lao; Stephanie A Parker; Chunyan Cai; Mohammad H Rahbar; James C Grotta
Journal:  Stroke       Date:  2014-01-14       Impact factor: 7.914

4.  A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.

Authors:  Jeanne Mendell; Robert J Noveck; Minggao Shi
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

Review 5.  Anticoagulant therapy in pediatrics.

Authors:  Mariam K Dabbous; Fouad R Sakr; Diana N Malaeb
Journal:  J Basic Clin Pharm       Date:  2014-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.